NCT03919591 is a NA clinical trial of Challenge virus RSV-A Memphis 37b in RSV Infection, sponsored by Hvivo.

Who is sponsoring NCT03919591?

NCT03919591 is sponsored by Hvivo.

What drugs are being tested in NCT03919591?

Interventions in NCT03919591: Challenge virus RSV-A Memphis 37b.

What condition does NCT03919591 study?

NCT03919591 studies RSV Infection.

Is NCT03919591 still recruiting?

NCT03919591 is currently completed. Last updated 14 October 2019.

Last reviewed 2019-10-14 · How we verify

NCT03919591

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RSV Study in Adults 60 to 75 Years of Age

Completed NA Last updated 14 October 2019

What this trial tests

NA trial testing Challenge virus RSV-A Memphis 37b in RSV Infection in 24 participants. Completed in 11 July 2019.

Timeline

12 March 2019

Primary endpoint
11 July 2019

11 July 2019

Quick facts

Lead sponsor	Hvivo
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	24
Start date	12 March 2019
Primary completion	11 July 2019
Estimated completion	11 July 2019
Sites	1 location across United Kingdom

Drugs / interventions tested

Challenge virus RSV-A Memphis 37b

Conditions studied

RSV Infection — all drugs for RSV Infection →

Sponsor

Hvivo — full company profile →

Who can join

Adults 60 to 75, any sex, with RSV Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to infect healthy volunteers aged 60-75 years old with Respiratory Syncytial Virus (RSV) to confirm how safe and well tolerated the use of an experimental RSV virus is in a population that has not previously received the virus. Additionally, this study will also look at various components of the volunteers' blood, the lining of their noses and other samples in order to measure the effects of the virus on the body, in particularly the immune system before, during and after viral infection.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group.
Jamrozik E, Littler K, Bull S, Emerson C, et al · · 2021 · cited 64× · PMID 33341309 · DOI 10.1016/j.vaccine.2020.10.075

Verify or expand the search:

Other recruiting trials for RSV Infection

Currently open trials in the same condition.

NCT06881953 — Prevention Strategy for Respiratory Syncytial Virus (RSV) Infections in Infants in France · recruiting
NCT06866405 — A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Sin · Phase 3 · recruiting
NCT06843317 — Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults · Phase 1 · recruiting
NCT06172660 — Real-World Effectiveness of Perinatal RSV Immunoprophylaxis · recruiting
NCT06640387 — CARE-ID: Dynamics of Respiratory Infections in Children and Transmission in Households and Schools · recruiting

Other Hvivo trials

Trials by the same sponsor.

NCT07189806 — Longitudinal Phenotyping and Endotyping Study in Adult Patients With Mild, Moderate, or Severe Asthma · recruiting
NCT06492564 — Dose, Safety and Pathogenicity of SARS-CoV-2 (COVID-19) Omicron Virus (BA.5) · EARLY_PHASE1 · completed
NCT06613737 — Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain · NA · completed
NCT06254820 — Dose, Safety, and Pathogenicity of a New Influenza B Strain · Phase 2 · unknown
NCT05572450 — Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge Strain · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03919591 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hvivo
Last refreshed: 14 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03919591.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing